Zevra Therapeutics Stock Today
| ZVRA Stock | 7.95 0.02 0.25% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Zevra Therapeutics is trading at 7.95 as of the 20th of March 2025, a 0.25% down since the beginning of the trading day. The stock's open price was 7.97. Zevra Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of April 2015 | Category Healthcare | Classification Health Care |
Zevra Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 54.12 M outstanding shares of which 5.78 M shares are at this time shorted by private and institutional investors with about 14.6 trading days to cover. More on Zevra Therapeutics
Moving against Zevra Stock
Zevra Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Neil McFarlane | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsZevra Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Zevra Therapeutics' financial leverage. It provides some insight into what part of Zevra Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Zevra Therapeutics (ZVRA) is traded on NASDAQ Exchange in USA. It is located in 1180 Celebration Boulevard, Celebration, FL, United States, 34747 and employs 59 people. Zevra Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 431.3 M. Zevra Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.12 M outstanding shares of which 5.78 M shares are at this time shorted by private and institutional investors with about 14.6 trading days to cover.
Zevra Therapeutics generates negative cash flow from operations
Check Zevra Therapeutics Probability Of Bankruptcy
Ownership AllocationZevra Therapeutics retains a total of 54.12 Million outstanding shares. Over half of Zevra Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Zevra Ownership Details
Zevra Therapeutics Historical Income Statement
Zevra Stock Against Markets
Zevra Therapeutics Corporate Management
| MD FFPM | Chief Officer | Profile | |
| Rahsaan JD | Secretary Officer | Profile | |
| Alison Peters | Chief Officer | Profile | |
| Nichol Ochsner | Vice Communications | Profile |
Already Invested in Zevra Therapeutics?
The danger of trading Zevra Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zevra Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zevra Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zevra Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.28) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.